DGAP: Developmental Genome Anatomy Project
DGAP:发育基因组解剖项目
基本信息
- 批准号:6322155
- 负责人:
- 金额:$ 113.19万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2001
- 资助国家:美国
- 起止时间:2001-04-01 至 2006-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (Applicant's Abstract): The goal of the Developmental
Genome Anatomy Project (DGAP) is to identify genes critical in human
development that are disrupted or dysregulated by balanced chromosomal
rearrangements in humans with multiple congenital anomalies. Approximately 1 in
2000 newborns has an apparently balanced rearrangement, with a 6.1 percent risk
for a serious congenital anomaly. These anomalies can include isolated defects
ranging from cleft palate/lip, abdominal wall defects, limb defects, cardiac
abnormalities or mental retardation, or they can occur as part of clinically
recognizable syndromes. Of particular relevance is the fact that de novo
structural abnormalities involving all chromosomes have been reported in
association with congenital anomalies; it has been speculated that a
significant number of such chromosomal breaks directly disrupt or dysregulate
genes critical to specific molecular pathways. We propose to study individuals
with multiple congenital anomalies and apparently balanced chromosomal
rearrangements, with the aim of using balanced chromosomal rearrangements as
signposts to identify these critical genes. The potential of DGAP will be
greatly enhanced by rapidly evolving genomic resources including the complete
human DNA sequence and an ordered FISH BAC map of the human genome.
Collaborations established between cytogeneticists and clinical geneticists
across the medical genetics community have been established to collect patient
samples with a variety of developmental defects and balanced chromosomal
rearrangements. Analysis of chromosomal breakpoints through FISH mapping
studies will be used to identify single genomic clones containing relevant
candidate sequences, and an online DGAP database is being created (Project 1).
Molecular identification and analysis of candidate genes, as well as mutation
studies in affected individuals will be the focus of subsequent studies
(Project 2). Identification of expression patterns assessing tissue or temporal
specificity will follow, as well as isolation of homologs in M. musculus and D.
melanogaster (Project 3). Ultimately, transgenic animals will be used to study
specific clones of interest to elucidate more fully their role in development
(Project 3). DGAP constitutes a multi-laboratory and multi-institutional
research endeavor which brings together the disciplines of clinical genetics,
cytogenetics, molecular biology and developmental genetics to illuminate genes
involved in fundamental pathways during human development.
描述(申请人摘要):发展的目标
基因组解剖计划(Genome Anatomy Project,DGAP)是一项旨在确定人类基因组中的关键基因的计划。
发育被平衡的染色体破坏或失调
基因重排的人与多重先天性异常。中约有1位
2000名新生儿有明显的平衡重排,风险为6.1%。
严重的先天性异常这些异常可能包括孤立的缺陷
范围从腭裂/唇腭裂、腹壁缺损、肢体缺损、心脏
异常或精神发育迟滞,或者它们可以作为临床上
可识别的综合征。特别重要的是,
涉及所有染色体的结构异常已在
与先天性异常有关;据推测,
大量这样染色体断裂直接破坏或失调
对特定分子途径至关重要的基因。我们建议研究个体
有多种先天性异常和明显的染色体平衡
重排,目的是使用平衡的染色体重排作为
来识别这些关键基因。DGAP的潜力将是
通过快速发展的基因组资源,包括完整的
人类DNA序列和人类基因组的有序FISH BAC图谱。
细胞遗传学家和临床遗传学家之间建立的合作
在医学遗传学界已经建立了收集病人
具有各种发育缺陷和平衡染色体的样品
重新安排染色体断裂点的FISH分析
研究将用于鉴定含有相关基因的单基因组克隆,
候选序列,并正在创建在线DGAP数据库(项目1)。
候选基因的分子鉴定和分析,以及突变
对受影响个体的研究将是后续研究的重点
(项目2)。评估组织或颞叶的表达模式的鉴定
特异性以及M中同源物的分离。musculus和D.
melanogaster(Project 3).最终,转基因动物将被用于研究
感兴趣的特定克隆,以更充分地阐明它们在发育中的作用
(项目3)。DGAP是一个多实验室和多机构
将临床遗传学、
细胞遗传学、分子生物学和发育遗传学来阐明基因
参与了人类发展的基本途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Cynthia Casson Morton其他文献
Investigating the shared genetic architecture of uterine leiomyoma and breast cancer: A genome-wide cross-trait analysis
研究子宫肌瘤和乳腺癌的共同遗传结构:全基因组跨性状分析
- DOI:
10.1016/j.ajhg.2022.05.015 - 发表时间:
2022 - 期刊:
- 影响因子:0
- 作者:
Xueyao Wu;Chenghan Xiao;Zhitong Han;Li Zhang;Xunying Zhao;Yu Hao;Jinyu Xiao;C Scott Gallagher;Peter Kraft;Cynthia Casson Morton;Jiayuan Li;Xia Jiang - 通讯作者:
Xia Jiang
Cynthia Casson Morton的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Cynthia Casson Morton', 18)}}的其他基金
SEQuencing a Baby for an Optimal Outcome (SEQaBOO)
对婴儿进行测序以获得最佳结果 (SEQaBOO)
- 批准号:
9021176 - 财政年份:2016
- 资助金额:
$ 113.19万 - 项目类别:
相似海外基金
The pathogenesis of ALG14-congenital disorders of glycosylation.
ALG14-先天性糖基化障碍的发病机制。
- 批准号:
23K14967 - 财政年份:2023
- 资助金额:
$ 113.19万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Identifying New Therapeutics and Molecular Mechanisms in Congenital Disorders of Glycosylation.
确定先天性糖基化疾病的新疗法和分子机制。
- 批准号:
10644811 - 财政年份:2023
- 资助金额:
$ 113.19万 - 项目类别:
Investigating the Genotype-Phenotype Relationships that Underlie Congenital Disorders with Cardiovascular Symptoms through Population-scale Analyses
通过人群规模分析研究具有心血管症状的先天性疾病背后的基因型-表型关系
- 批准号:
10724185 - 财政年份:2023
- 资助金额:
$ 113.19万 - 项目类别:
Identifying understudied protein-related glycoproteome disruption in Congenital Disorders of Glycosylation
识别先天性糖基化障碍中尚未研究的蛋白质相关糖蛋白组破坏
- 批准号:
10725869 - 财政年份:2023
- 资助金额:
$ 113.19万 - 项目类别:
Pathogenic Mechanisms of Congenital Disorders of Glycosylation
先天性糖基化障碍的发病机制
- 批准号:
10633548 - 财政年份:2023
- 资助金额:
$ 113.19万 - 项目类别:
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10480649 - 财政年份:2022
- 资助金额:
$ 113.19万 - 项目类别:
Assessment of a potential application of endogenous stem cells to treat congenital disorders
评估内源干细胞治疗先天性疾病的潜在应用
- 批准号:
22K20740 - 财政年份:2022
- 资助金额:
$ 113.19万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
Targeting aldose reductase: A Phase IIb/III trial for the novel use of Epalrestat to treat Congenital Disorders of Glycosylation (PMM2-CDG)
靶向醛糖还原酶:依帕司他新用途治疗先天性糖基化障碍 (PMM2-CDG) 的 IIb/III 期试验
- 批准号:
10616658 - 财政年份:2022
- 资助金额:
$ 113.19万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10040788 - 财政年份:2020
- 资助金额:
$ 113.19万 - 项目类别:
O-glycosylation mechanisms of neurological deficits in congenital disorders of glycosylation
先天性糖基化障碍神经功能缺损的O-糖基化机制
- 批准号:
10250486 - 财政年份:2020
- 资助金额:
$ 113.19万 - 项目类别: